<SEC-DOCUMENT>0001171843-23-003835.txt : 20230608
<SEC-HEADER>0001171843-23-003835.hdr.sgml : 20230608
<ACCEPTANCE-DATETIME>20230608161506
ACCESSION NUMBER:		0001171843-23-003835
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230608
FILED AS OF DATE:		20230608
DATE AS OF CHANGE:		20230608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		231002072

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_060823.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of June 2023</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39777</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Nanobiotix S.A.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>60 Rue de Wattignies 75012 Paris, France</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>&#160;</p><p>&#160;</p><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p>--><hr style="page-break-after: always;" noshade="noshade" /><p> <p>On June 8, 2023, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br /><a href="exh_991.htm">(c) Exhibit 99.1. Press release dated June 8, 2023</a></p></p><p /><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;Nanobiotix S.A.&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: June 8, 2023</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Bart Van Rhijn&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Bart Van Rhijn</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Chief Financial Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Voting Rights and Shares Capital of the Company</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
   <p align="center"><strong><em>In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit&#233; des March&#233;s Financiers)</em></strong></p>    <p>PARIS, June  08, 2023  (GLOBE NEWSWIRE) -- <br >Market: Euronext Paris&#160;/ Nasdaq<br >Euronext Compartment: B <br >ISIN code: FR0011341205<br >Nasdaq: NBTX<br >Bloomberg: NANO:FP<br >Reuters: NANO.PA<br >Website: www.nanobiotix.com</p>  <table style="width:100%; border-collapse:collapse !important;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; "><tr><td rowspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Date</strong><br ></td><td rowspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Number of Shares<br > Outstanding</strong><br ></td><td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Total number of voting rights</strong></td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Total voting rights, theoretical</strong><sup><strong>1</strong></sup><br ><br ></td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Total voting rights, </strong><br ><strong>exercisable</strong><sup><strong>2</strong></sup></td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; ">May 31, 2023<br ><br ></td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; ">34,875,872</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; ">36,622,309</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; ">36,600,191</td></tr></table>  <p align="justify">According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix&#8217;s capital if those figures differ from the information previously disclosed.</p>    <p align="justify"><strong>About NANOBIOTIX</strong></p>    <p align="justify">Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.&#160;</p>    <p align="justify">For more information about Nanobiotix, visit us at <u>www.nanobiotix.com</u> or follow us on <u>LinkedIn</u> and <u>Twitter</u><u>.</u>&#160;</p>    <p align="justify"><strong>Contacts</strong></p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><em>Nanobiotix </em></td></tr><tr><td style="border-bottom: solid black 1pt ; vertical-align: top ; "><br ><strong>Nanobiotix Communications</strong><br ><em>Brandon Owens</em><br ><em>VP, Communications</em><br >+1 (617) 852-4835<br ><u>contact@nanobiotix.com</u><br ><br ></td><td style="border-top: solid black 1pt ; vertical-align: top ; "><br ><strong>Nanobiotix Investor Relations </strong><br ><em>Craig West</em><br ><em>SVP, Investor Relations</em><br >+1 (617) 583-0211&#160;<br ><u>investors@nanobiotix.com</u><br ><br ></td></tr><tr><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><em>Media Relations</em></td></tr><tr><td style="vertical-align: top ; "><br ><br >France &#8211; <strong>Ulysse Communication<br ></strong>Pierre-Louis Germain<br >+ 33 (0) 6 64 79 97 51<br >plgermain@ulysse-communication.com</td><td style="vertical-align: top ; "><strong><br ></strong><br ><strong>LifeSci Advisors</strong>&#160;<br ><em>Ligia Vela-Reid</em>&#160;<br >+44 (0) 7413825310&#160;<br ><u>lvela-reid@lifesciadvisors.com</u></td></tr></table>  <p>&#160;</p>    <hr >    <p align="justify"><sup>1</sup> <sub><em>The total number of theoretical (or &#8220;gross&#8221;) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.</em></sub></p>    <p align="justify"><sup>2</sup> <sub><em>The total number of exercisable at a Shareholders&#8217; Meeting (or &#8220;net&#8221;) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.</em></sub>&#160;</p>    <p align="justify"><strong>Attachment</strong><br ></p>    <ul id="gnw_attachments_section-items"><li>2023-06-08 -- NBTX -- Voting Rights -- FINAL&#160;(https://ml.globenewswire.com/Resource/Download/ed95befc-6f75-4635-8727-e26d3ca0ee9b)</li></ul> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
